BJH - 2018, issue Abstract Book BHS, february 2018
B. Stamatopoulos , T. Smith , E. Crompot , K. Pieters , R. Clifford , M. Mraz , P. Robbe , A. Burns , A. Timbs , D. Bruce , P. Hillmen , N. Meuleman MD, PhD, P. Mineur MD, R. Firescu , M. Maerevoet MD, V. De Wilde MD, PhD, A. Efira MD, J. Philippé MD, PhD, B. Verhasselt MD, PhD, F. Offner MD, PhD, A. Heger , D. Sims , H. Dreau , A. Schuh
A. Rombout PhD, B. Verhasselt MD, PhD, J. Philippé MD, PhD
A typical hallmark of chronic lymphocytic leukaemia is its clinical heterogeneity, which is reflected by the presence or absence of several prognostic factors, such as cell surface molecules, genetic lesions and microRNAs. Despite having established prognostic value, the functional implications of most of these biomarkers remains poorly defined. The aim of this work was to gain more insight into the role of the B cell receptor and associated prognostic markers ZAP70 and LPL in the biology of chronic lymphocytic leukaemia.